email article
Ready-to-use dasiglucagon (Zegalogue) an aqueous formula of a glucagon analogue reversed hypoglycemia for patients with type 1 diabetes in a median of 10 minutes, while plasma glucose recovery was achieved within 15 minutes for 99% of patients, according to phase III trial results. (
Diabetes Care)
Within the first few months of starting gender-affirming hormone therapy, mean systolic blood pressure was lower by 4 mm Hg for transfeminine individuals and higher by 2.6 mm Hg for transmasculine individuals. (
Hypertension)
Novo Nordisk is slated to test its oral semaglutide, approved for diabetes under the trade name Rybelsus, for obesity in a phase III trial after great success with once-weekly injectable semaglutide, which is marketed for diabetes under the name Ozempic. (
UTHSC researchers receive $1.99 million to advance understanding of diabetes pathophysiology
The National Institute of Diabetes and Digestive and Kidney Diseases recently awarded a team of UTHSC researchers $1.99 million for their work to advance understanding of the pathophysiology of prediabetes, diabetes, and related complications. Sam Dagogo-Jack, MD, professor of Medicine and director of the General Clinical Research Center, is a principal investigator, along with Nawajes Mandal, PhD, associate professor in the Departments of Ophthalmology, Anatomy and Neurobiology, and Pharmaceutical Sciences. Their project is titled Ceramides and Sphingolipids as Predictors of Incident Dysglycemia.
Dr. Dagogo-Jack is a leading clinical researcher and an expert on diabetes and prediabetes. Dr. Mandal is a basic scientist and a leading expert on the role of bioactive lipid signlaing, like sphingolipids (SPLs) and ceramides, in human ocular, metabolic, neurodegeneration, and inflammatory dise